Feb. 4, 2013
/PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today reported that upon further analysis of the
data reported on January 9th, 2013
, the striatal reinnervation (densitometry) data produced in the 6 hydroxydopamine (6-OHDA) neurorestoration rat model of Parkinson's disease for MANF at 36ug achieved a statistically significant improvement over the data produced for GDNF, with a P value of 0.047.
"The statistical significance uncovered from our in-depth analysis underscores the challenges of evaluating dosing regimens for MANF in standard unilateral rodent models of Parkinson's disease due to MANF's unique ability to reinnervate the striatum," said Dr.
John W. Commissiong
, Chief Scientist at Amarantus. "We have been cautious in reporting this first of its kind data thus far, and intend to update the marketplace regarding certain aspects of our further analysis as we move forward. The Company is now preparing to initiate IND-enabling studies."
The Company has retained a Swiss neuroscience-focused consulting firm to conduct a full audit of the data derived from these experiments and assist the Company in planning for its IND package. The Company will be reporting additional rodent data in the first quarter on a 6-OHDA neuroprotection rat model of Parkinson's disease where both MANF and GDNF were delivered to the substantia nigra. The final report for all rodent experiments will be made public in the second quarter following completion of the data audit.
About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (Programmed Cell Death). Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (in response to injury or disease), via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's current lead indication is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI). Future indications may include myocardial infarction and certain rare and ultra-rare orphan diseases where MANF is currently being evaluated.